Avalo Therapeutics
AVTX
AVTX
66 hedge funds and large institutions have $195M invested in Avalo Therapeutics in 2025 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
83% more funds holding
Funds holding: 36 → 66 (+30)
44.03% more ownership
Funds ownership: 72.44% → 116.46% (+44%)
Holders
66
Holding in Top 10
–
Calls
$1.39M
Puts
$659K
Top Buyers
| 1 | +$13.4M | |
| 2 | +$10.6M | |
| 3 | +$10.4M | |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$9.16M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.68M |
Top Sellers
| 1 | -$5.37M | |
| 2 | -$3.43M | |
| 3 | -$2.22M | |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$919K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$490K |
